. 2015 Oct 16;10(10):e0140618. doi: 10.1371/journal.pone.0140618

Table 6. Comparison of fasting serum levels of sCD26/DPP-IV between combination therapy without metformin, combination therapy with metformin, monotherapy with metformin and non- treated among subjects with type 2 diabetes.

	^* SU +TZD w/wo insulin(n = 28)	Metformin + SU + TZD w/wo insulin (n = 241)	P-Value	Monotherapy with metformin (n = 34)	P-Value	Non-treated (n = 8)	P-Value
Parameter	^* SU +TZD w/wo insulin(n = 28)	Metformin + SU + TZD w/wo insulin (n = 241)	P-Value	Monotherapy with metformin (n = 34)	P-Value	Non-treated (n = 8)	P-Value
sCD26/DPP-IV (ng/mL)	1355 (166.0)	1205 (229.1)	^a 0.023	1048 (275.4)	^a 2.9×10 ⁻⁵, ^b 0.001	1123 (302.0)	^a 0.056, ^b 0.385, ^c 0.432

The results presented represent geometric means (SD), adjusted for age, gender, and race

^avs combination therapy without metformin (SU + TZD with or without insulin)

^bvs combination therapy with metformin (metformin + SU + TZD with or without insulin)

^cvs monotherapy with Metformin which evaluated by univariate (General Linear Model).

Bold values are significant.

*Sulfonylurea (SU), Thiazolidinedione (TZD) with or without insulin.